Table 1.
Basic clinicopathological characteristics of patients in cohort 1
| Variables | Total patients | ||
|---|---|---|---|
| No. of patients (%) | P values* (exoPD-L1) | P values* (sPD-L1) | |
| Age | |||
| > = 65 | 39 (22.03) | 0.873 | 0.544 |
| < 65 | 138 (77.97) | ||
| Gender | |||
| Male | 120 (67.80) | 0.254 | 0.596 |
| Female | 57 (32.20) | ||
| Pathological grade | |||
| G1–2 | 137 (77.40) | 0.112 | 0.003 |
| G3 | 40 (22.60) | ||
| Histological subtype | |||
| Non-mucinous | 172 (97.18) | 0.633 | 0.541 |
| Mucinous | 5 (2.82) | ||
| Primary tumor T stage | |||
| Tis-3 | 117(66.10) | 0.709 | 0.032 |
| T4 | 47(26.55) | ||
| Missing | 13(7.35) | ||
| Primary tumor N stage | |||
| N0 | 62 (35.03) | 0.030 | 0.087 |
| N1-2 | 107 (60.45) | ||
| Missing | 8 (4.52) | ||
| Primary tumor site | |||
| Right-sided | 35 (19.77) | 0.896 | 0.543 |
| Left-sided | 142 (80.23) | ||
| Primary tumor size | 0.873 | 0.708 | |
| ≤ 5 cm | 83 (46.89) | ||
| > 5 cm | 25 (14.12) | ||
| Missing | 69 (38.98) | ||
| Vascular invasion | 0.051 | 0.008 | |
| No | 97(54.80) | ||
| Yes | 27(15.30) | ||
| Missing | 53(29.94) | ||
| Nerve invasion | 0.981 | 0.802 | |
| No | 85(48.02) | ||
| Yes | 39(22.03) | ||
| Missing | 53(29.95) | ||
| Preoperative CEA | 0.044 | 0.066 | |
| ≤ 200 ng/ml | 167 (94.35) | ||
| > 200 ng/ml | 10 (5.65) | ||
| Interval from primary tumor resection to liver metastases | 0.197 | ||
| ≤ 12 months | 146 (82.49) | ||
| > 12 months | 31 (17.51) | ||
| Number of metastases per patient | 0.994 | 0.433 | |
| ≤ 1 | 76 (42.94) | ||
| > 1 | 101 (57.06) | ||
| Size of the largest metastasis | 0.009 | 0.013 | |
| ≤ 5 cm | 154 (87.01) | ||
| > 5 cm | 23 (12.99) | ||
| Resection type of liver metastasis and primary tumor | 0.994 | 0.125 | |
| Simultaneous resection | 90 (50.8) | ||
| Staged resection | 87 (40.2) | ||
| Preoperative chemotherapy | 0.326 | 0.088 | |
| No | 88(49.72) | ||
| Yes | 89 (50.28) | ||
| Chemotherapy | 60 (33.90) | ||
| Cetuximab-based | 17 (9.60) | ||
| Bevacizumab-based | 12 (6.78) | ||
| Postoperative chemotherapy | 0.996 | 0.766 | |
| No | 46 (25.99) | ||
| Yes | 131 (74.01) | ||
| Chemotherapy | 109(61.58) | ||
| Cetuximab-based | 14 (7.91) | ||
| Bevacizumab-based | 8 (4.52) | ||
| Ablation | 0.974 | 0.774 | |
| No | 153(86.40) | ||
| Yes | 24(13.60) | ||
| CRS | 0.021 | 0.057 | |
| 0–2 | 102 (57.63) | ||
| 3–5 | 67 (47.85) | ||
| Missing | 8 (4.52) | ||
| KRAS | 0.063 | 0.065 | |
| Wild-type | 61 (34.46) | ||
| Mutation-type | 22 (12.43) | ||
| Missing | 94 (53.11) | ||
*Correlation between basic clinicopathological characteristics and exoPD-L1 or Spd-l1 using Kendall’s tau-b correlation test